Premature ovarian failure: Clinical presentation and treatment

Obstetrics and Gynecology Clinics of North America

Volumn 42, Issue 1, 2015, Pages 153-161

  Kovanci, Ertug ^a   Schutt, Amy K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Autoimmune disorders; Estrogen therapy; Heart disease; Infertility; Osteoporosis; Ovarian failure

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; FOLLITROPIN; FOLLITROPIN RECEPTOR; LUTEINIZING HORMONE RECEPTOR; OSPEMIFENE; PROGESTERONE; THYROTROPIN; VITAMIN D; GONADORELIN;

ADRENAL INSUFFICIENCY; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOSOMAL DISORDER; BONE MASS; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DISTRESS SYNDROME; DRUG MEGADOSE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSPAREUNIA; FERTILIZATION IN VITRO; FRAGILE X SYNDROME; GENE DELETION; GENETIC ASSOCIATION; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INFERTILITY; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KARYOTYPE; MORTALITY; MYASTHENIA GRAVIS; ORAL CONTRACEPTION; ORAL CONTRACEPTIVE USE; OSTEOLYSIS; OSTEOPOROSIS; PERNICIOUS ANEMIA; PHENOTYPE; POSTMENOPAUSE; PREMATURE OVARIAN FAILURE; PRIMARY AMENORRHEA; REVIEW; RHEUMATOID ARTHRITIS; SECONDARY AMENORRHEA; SEXUAL DYSFUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TURNER SYNDROME; VITAMIN SUPPLEMENTATION; X CHROMOSOME ABERRATION; AGONISTS; COMPLICATION; DEFICIENCY; FEMALE; INFERTILITY, FEMALE; OOCYTE DONATION; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROCEDURES; PROGNOSIS;

ESTROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY, FEMALE; OOCYTE DONATION; OSTEOPOROSIS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY; PROGNOSIS;

EID: 84922523056     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2014.10.004     Document Type: Review

References (34)

1. Coulam C.B., Adamson S.C., Annegers J.F. Incidence of premature ovarian failure. Obstet Gynecol 1986, 67(4):604-606.
2. Jacobsen B.K., Heuch I., Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003, 157(10):923-929.
3. Kovanci E., Rohozinski J., Simpson J.L., et al. Growth differentiating factor-9 mutations may be associated with premature ovarian failure. Fertil Steril 2007, 87(1):143-146.
4. Simpson J.L. Genetic and phenotypic heterogeneity in ovarian failure: overview of selected candidate genes. Ann N Y Acad Sci 2008, 1135:146-154.
5. Welt C.K. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008, 68(4):499-509.
6. Simpson J.L., Elias S. Genetics in obstetrics and gynecology 2003, Saunders, Philadelphia. 3rd edition.
7. Hook E.B., Warburton D. The distribution of chromosomal genotypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Hum Genet 1983, 64(1):24-27.
8. Simpson J.L., Rajkovic A. Ovarian differentiation and gonadal failure. Am J Med Genet 1999, 89(4):186-200.
9. Wolff A.S., Erichsen M.M., Meager A., et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. JClin Endocrinol Metab 2007, 92(2):595-603.
10. Simon A.M., Goodenough D.A., Li E., et al. Female infertility in mice lacking connexin 37. Nature 1997, 385(6616):525-529.
11. Dunn H.G., Meuwissen H., Livingstone C.S., et al. Ataxia-telangiectasia. Can Med Assoc J 1964, 91:1106-1118.
12. McKinnon P.J. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol 2012, 7:303-321.
13. De Baere E., Dixon M.J., Small K.W., et al. Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype-phenotype correlation. Hum Mol Genet 2001, 10(15):1591-1600.
14. Sherman S.L. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000, 97(3):189-194.
15. Ennis S., Ward D., Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 2006, 14(2):253-255.
16. Nelson L.M. Clinical practice. Primary ovarian insufficiency. NEngl J Med 2009, 360(6):606-614.
17. He C., Kraft P., Chen C., et al. Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet 2009, 41(6):724-728.
18. Knauff E.A., Franke L., van Es M.A., et al. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum Reprod 2009, 24(9):2372-2378.
19. Perry J.R., Corre T., Esko T., et al. Agenome-wide association study of early menopause and the combined impact of identified variants. Hum Mol Genet 2013, 22(7):1465-1472.
20. American College of Obstetricians and Gynecologists ACOG Committee opinion no. 469: carrier screening for fragile X syndrome. Obstet Gynecol 2010, 116(4):1008-1010.
21. van der Stege J.G., Groen H., van Zadelhoff S.J., et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008, 15(1):23-31.
22. Takebayashi K., Takakura K., Wang H., et al. Mutation analysis of the growth differentiation factor-9 and -9B genes in patients with premature ovarian failure and polycystic ovary syndrome. Fertil Steril 2000, 74(5):976-979.
23. Karnis M.F. Fertility, pregnancy, and medical management of Turner syndrome in the reproductive years. Fertil Steril 2012, 98(4):787-791.
24. Atsma F., Bartelink M.L., Grobbee D.E., et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13(2):265-279.
25. Lokkegaard E., Jovanovic Z., Heitmann B.L., et al. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006, 53(2):226-233.
26. Kalantaridou S.N., Naka K.K., Papanikolaou E., et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. JClin Endocrinol Metab 2004, 89(8):3907-3913.
27. Mondul A.M., Rodriguez C., Jacobs E.J., et al. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005, 162(11):1089-1097.
28. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291(14):1701-1712.
29. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
30. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007, 115(7):840-845.
31. Renoux C., Dell'aniello S., Garbe E., et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010, 340:c2519.
32. Bachmann G.A., Komi J.O., Ospemifene Study Group Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 2010, 17(3):480-486.
33. Kangas L., Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids 2013, 78(12-13):1273-1280.
34. Khan S.N., Craig L., Wild R. Osteoporosis: therapeutic guidelines. Guidelines for practice management of osteoporosis. Clin Obstet Gynecol 2013, 56(4):694-702.